glycine has been researched along with Melanoma in 28 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma." | 7.66 | Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982) |
| "Malignant melanoma is a highly aggressive tumor resistant to chemotherapy." | 5.46 | Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017) |
| " Our objective was to precisely assess changes in α-syn levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines following acute exposure to pesticides (rotenone, paraquat, maneb, and glyphosate) using Western blot and flow cytometry." | 3.79 | Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. ( Andrieu, T; Baron, T; Bétemps, D; Chorfa, A; Hogeveen, K; Lazizzera, C; Morignat, E, 2013) |
| "N-Diazoacetyl derivatives of glycine and phenylalanine show antitumor activity in mice bearing P388 leukemia or B16 melanoma." | 3.66 | Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. ( Baldini, L; Giraldi, T; Sava, G, 1982) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| "Malignant melanoma is a highly aggressive tumor resistant to chemotherapy." | 1.46 | Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. ( Guo, XL; Jiang, BP; Liang, H; Shen, XC; Wang, Y; Zhang, L; Zhu, Y, 2017) |
| "Six CDKN2A families had pancreatic cancer." | 1.31 | Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "The putative metastasis suppressor genes, NME1(nm23-1) and NME2(nm23-2), were examined in a model system we developed to approximate the dissemination of melanoma from a primary skin tumor." | 1.29 | Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials. ( Backer, JM; Hamby, CV; Mendola, CE; Potla, L; Stafford, G, 1995) |
| "Many BRMs have been used in treatment of melanoma, e." | 1.28 | Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. ( Hayasaka, K; Ishihara, K; Yamazaki, N, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (21.43) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Liu, X | 1 |
| Chen, Y | 1 |
| Xu, R | 1 |
| He, S | 1 |
| Pizzato Scomazzon, S | 1 |
| Riccio, A | 1 |
| Santopolo, S | 1 |
| Lanzilli, G | 1 |
| Coccia, M | 1 |
| Rossi, A | 1 |
| Santoro, MG | 1 |
| Yan, C | 1 |
| Saleh, N | 1 |
| Yang, J | 2 |
| Nebhan, CA | 1 |
| Vilgelm, AE | 1 |
| Reddy, EP | 1 |
| Roland, JT | 1 |
| Johnson, DB | 1 |
| Chen, SC | 1 |
| Shattuck-Brandt, RL | 1 |
| Ayers, GD | 1 |
| Richmond, A | 1 |
| Saei, A | 1 |
| Palafox, M | 1 |
| Benoukraf, T | 1 |
| Kumari, N | 1 |
| Jaynes, PW | 1 |
| Iyengar, PV | 1 |
| Muñoz-Couselo, E | 1 |
| Nuciforo, P | 1 |
| Cortés, J | 1 |
| Nötzel, C | 1 |
| Kumarakulasinghe, NB | 1 |
| Richard, JLC | 1 |
| Bin Adam Isa, ZF | 1 |
| Pang, B | 1 |
| Guzman, M | 1 |
| Siqin, Z | 1 |
| Yang, H | 1 |
| Tam, WL | 1 |
| Serra, V | 1 |
| Eichhorn, PJA | 1 |
| Mu, LM | 1 |
| Liu, L | 1 |
| Liu, R | 1 |
| Du, YF | 1 |
| Luo, Q | 1 |
| Xu, JR | 1 |
| Xie, Y | 1 |
| Lu, WL | 1 |
| Chorfa, A | 1 |
| Bétemps, D | 1 |
| Morignat, E | 1 |
| Lazizzera, C | 1 |
| Hogeveen, K | 1 |
| Andrieu, T | 1 |
| Baron, T | 1 |
| Fortes, C | 1 |
| Mastroeni, S | 1 |
| Segatto M, M | 1 |
| Hohmann, C | 1 |
| Miligi, L | 1 |
| Bakos, L | 1 |
| Bonamigo, R | 1 |
| Cheewinthamrongrod, V | 1 |
| Kageyama, H | 1 |
| Palaga, T | 1 |
| Takabe, T | 1 |
| Waditee-Sirisattha, R | 1 |
| Suarez-Kelly, LP | 1 |
| Kemper, GM | 1 |
| Duggan, MC | 1 |
| Stiff, A | 1 |
| Noel, TC | 1 |
| Markowitz, J | 1 |
| Luedke, EA | 1 |
| Yildiz, VO | 1 |
| Yu, L | 1 |
| Jaime-Ramirez, AC | 1 |
| Karpa, V | 1 |
| Zhang, X | 1 |
| Carson, WE | 1 |
| Muqaku, B | 1 |
| Eisinger, M | 1 |
| Meier, SM | 1 |
| Tahir, A | 1 |
| Pukrop, T | 1 |
| Haferkamp, S | 1 |
| Slany, A | 1 |
| Reichle, A | 1 |
| Gerner, C | 1 |
| Jiang, BP | 1 |
| Zhang, L | 1 |
| Guo, XL | 1 |
| Shen, XC | 1 |
| Wang, Y | 1 |
| Zhu, Y | 1 |
| Liang, H | 1 |
| Venè, R | 1 |
| Castellani, P | 1 |
| Delfino, L | 1 |
| Lucibello, M | 1 |
| Ciriolo, MR | 1 |
| Rubartelli, A | 1 |
| Miao, Y | 1 |
| Jalili, A | 1 |
| Wagner, C | 1 |
| Pashenkov, M | 1 |
| Pathria, G | 1 |
| Mertz, KD | 1 |
| Widlund, HR | 1 |
| Lupien, M | 1 |
| Brunet, JP | 1 |
| Golub, TR | 1 |
| Stingl, G | 1 |
| Fisher, DE | 1 |
| Ramaswamy, S | 1 |
| Wagner, SN | 1 |
| Yamashina, S | 1 |
| Ikejima, K | 1 |
| Rusyn, I | 2 |
| Sato, N | 1 |
| Sava, G | 1 |
| Giraldi, T | 1 |
| Baldini, L | 1 |
| Thomasset, N | 1 |
| Quash, GA | 1 |
| Doré, JF | 1 |
| Hamby, CV | 1 |
| Mendola, CE | 1 |
| Potla, L | 1 |
| Stafford, G | 1 |
| Backer, JM | 1 |
| Kask, K | 1 |
| Berthold, M | 1 |
| Kahl, U | 1 |
| Nordvall, G | 1 |
| Bartfai, T | 1 |
| Ts'ao, C | 1 |
| Molteni, A | 1 |
| Taylor, JM | 1 |
| Rose, ML | 2 |
| Madren, J | 1 |
| Bunzendahl, H | 1 |
| Thurman, RG | 2 |
| Goldstein, AM | 1 |
| Struewing, JP | 1 |
| Chidambaram, A | 1 |
| Fraser, MC | 1 |
| Tucker, MA | 1 |
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Bradford, B | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Ishihara, K | 1 |
| Hayasaka, K | 1 |
| Yamazaki, N | 1 |
| Knudsen, BS | 1 |
| Harpel, PC | 1 |
| Nachman, RL | 1 |
| Pasztor, LM | 1 |
| Hu, F | 1 |
| Stankova, L | 1 |
| Bigley, R | 1 |
| Schulman, JD | 1 |
| Wrathall, JR | 1 |
| Silagi, S | 1 |
| Doores, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01205815] | 3,000 participants (Anticipated) | Observational | 2010-06-03 | Recruiting | |||
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
1 review available for glycine and Melanoma
| Article | Year |
|---|---|
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
27 other studies available for glycine and Melanoma
| Article | Year |
|---|---|
KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
Topics: Annexins; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Glycine; Histones; Humans; Jumo | 2022 |
The Zinc-Finger AN1-Type Domain 2a Gene Acts as a Regulator of Cell Survival in Human Melanoma: Role of E3-Ligase cIAP2.
Topics: Baculoviral IAP Repeat-Containing 3 Protein; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Tra | 2019 |
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Topics: Animals; Antineoplastic Agents; CD40 Antigens; Female; Glycine; Humans; Immune Checkpoint Inhibitors | 2021 |
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
Topics: Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; F-Box-WD Repeat-Co | 2018 |
Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma.
Topics: Animals; Cancer Vaccines; Cytokines; Disease Models, Animal; Female; Glycine; Humans; Immunomodulati | 2019 |
Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
Topics: alpha-Synuclein; Cell Death; Cell Line, Tumor; Cell Survival; Glycine; Glyphosate; Humans; Insectici | 2013 |
Occupational Exposure to Pesticides With Occupational Sun Exposure Increases the Risk for Cutaneous Melanoma.
Topics: Adult; Aged; Brazil; Case-Control Studies; Female; Fungicides, Industrial; Glycine; Glyphosate; Herb | 2016 |
DNA damage protecting and free radical scavenging properties of mycosporine-2-glycine from the Dead Sea cyanobacterium in A375 human melanoma cell lines.
Topics: Antioxidants; Cell Line, Tumor; Cyanobacteria; Cyclohexanols; DNA Damage; Free Radical Scavengers; G | 2016 |
The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2016 |
Multi-omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma.
Topics: Asparagine; Biomarkers, Tumor; Blood Platelets; Cachexia; Calcium; Glycine; Humans; Melanoma; Metabo | 2017 |
Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma.
Topics: Animals; Cell Death; Cell Line, Tumor; Glycine; Humans; Hyaluronic Acid; Hyperthermia, Induced; Infr | 2017 |
The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
Topics: Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Cell Survival | 2011 |
Substitution of Gly with Ala enhanced the melanoma uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide.
Topics: alpha-MSH; Animals; Binding, Competitive; Cell Line, Tumor; Glycine; Inhibitory Concentration 50; Me | 2012 |
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cycl | 2012 |
Glycine as a potent anti-angiogenic nutrient for tumor growth.
Topics: Calcium; Cell Movement; Chloride Channels; Endothelium, Vascular; Glycine; Humans; In Vitro Techniqu | 2007 |
Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Glycine; Leukemia, Experimental; Melanoma; Mice; Neop | 1982 |
The differential contribution of arginase and transamidinase to ornithine biosynthesis in two achromic human melanoma cell lines.
Topics: Amidinotransferases; Arginase; Arginine; Cell Line; Glycine; Humans; Hydrogen-Ion Concentration; Mel | 1982 |
Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cell Line; Clone Cells; DNA Primers; Gene Expression; G | 1995 |
Delineation of the peptide binding site of the human galanin receptor.
Topics: Alanine; Amino Acid Sequence; Animals; Binding Sites; Cell Membrane; Cloning, Molecular; Conserved S | 1996 |
Injury-specific cytotoxic response of tumor cells and endothelial cells.
Topics: Animals; Cattle; Cells, Cultured; Chromium Radioisotopes; Endopeptidases; Endothelium, Vascular; Gly | 1996 |
Dietary glycine inhibits the growth of B16 melanoma tumors in mice.
Topics: Animals; Cell Division; Cell Line; Diet; Glycine; Melanoma; Mice; Neovascularization, Pathologic; Sk | 1999 |
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G | 2000 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
Topics: Biological Factors; Biological Products; Cell Wall Skeleton; Cytokines; DNA, Bacterial; Glycine; Hum | 1989 |
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.
Topics: Animals; Cattle; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Extracellular Matrix; Glycine | 1987 |
8-Azaguanine-resistant melanoma cells in vitro and in vivo.
Topics: Aminopterin; Animals; Azaguanine; Bromodeoxyuridine; Cell Division; Cell Fusion; Cell Line; Drug Res | 1974 |
Altered amino acid concentrations accompanying suppression of malignancy of mouse melanoma cells by 5-bromodeoxyuridine.
Topics: Alanine; Amino Acids; Animals; Asparagine; Bromodeoxyuridine; Cells, Cultured; Glutamates; Glutamine | 1974 |